Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vaccine against Alzheimer's disease (AD). In preparation of this vaccine, we sensitized the isolated dendritic cells ex vivo with Aβ peptide, and administered these sensitized dendritic cells as a the...
Guardado en:
Autores principales: | Neel R Nabar, Fang Yuan, Xiaoyang Lin, Li Wang, Ge Bai, Jonathan Mayl, Yaqiong Li, Shu-Feng Zhou, Jinhuan Wang, Jianfeng Cai, Chuanhai Cao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b3d47ae47c0f4d59b889ae0486f25323 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Milrinone Ameliorates the Neuroinflammation and Memory Function of Alzheimer’s Disease in an APP/PS1 Mouse Model
por: Chen Q, et al.
Publicado: (2021) -
Sevoflurane Promotes Neurodegeneration Through Inflammasome Formation in APP/PS1 Mice
por: Guohua Li, et al.
Publicado: (2021) -
Author Correction: Untargeted lipidomics reveals progression of early Alzheimer’s disease in APP/PS1 transgenic mice
por: Xueju Zhang, et al.
Publicado: (2021) -
Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer’s Disease-Related Pathology in APP/PS-1 Mice
por: Kong L, et al.
Publicado: (2020) -
Early synaptic deficits in the APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A2A receptors
por: Silvia Viana da Silva, et al.
Publicado: (2016)